Calendar

Week of Apr 27, 2026

Apr 30, 2026phase 2 completion104d agoOhio State University Comprehensive Cancer Center — canakinumab (Phase II Trial Completion)canakinumab

Therapy area: Oncology. Indication: Lung Cancer

full page →canakinumab →source: globaldata

Apr 30, 2026phase 2 completion104d agoNational Cancer Institute US — ipilimumab (Phase II Trial Completion)ipilimumab

Therapy area: Oncology. Indication: Endometrial Cancer

full page →ipilimumab →source: globaldata

Apr 30, 2026phase 2 completion104d agoBioCanRx — ipilimumab (Phase II Trial Completion)ipilimumab

Therapy area: Oncology. Indication: Kidney Cancer (Renal Cell Cancer), Metastatic Renal Cell Carcinoma

full page →ipilimumab →source: globaldata

Apr 30, 2026phase 2 completion104d agoNanjing First Hospital — amoxicillin (Phase II Trial Completion)amoxicillin

Therapy area: Infectious Disease. Indication: Helicobacter pylori Infections

full page →amoxicillin →source: globaldata

Apr 30, 2026phase 2 completion104d agoChinese Academy of Medical Sciences and Peking Union Medical College — fuzuloparib (Phase II Trial Completion)fuzuloparib

Therapy area: Oncology. Indication: Soft Tissue Sarcoma

full page →fuzuloparib →source: globaldata

Apr 30, 2026phase 2 completion104d agoSun Pharmaceutical Industries Ltd — Absorica (Phase II Trial Completion)ISOTRETINOIN

Therapy area: Oncology. Indication: Neuroblastoma

full page →ISOTRETINOIN →source: globaldata

Apr 30, 2026phase 2 completion104d agoDutch Heart Foundation — ghrelin (Phase II Trial Completion)ghrelin

Therapy area: Cardiovascular. Indication: Acute Ischemic Stroke, Ischemic Stroke

full page →ghrelin →source: globaldata

Apr 30, 2026phase 2 completion104d agoInstituto de Investigacion sanitaria de Santiago de Compostela — Vacucis (Phase II Trial Completion)Vacucis

Therapy area: Infectious Disease, Mouth and Dental Disorders. Indication: Candidiasis, Xerostomia

full page →Vacucis →source: globaldata

Apr 30, 2026phase 2 completion104d agoArcus Biosciences Inc — atezolizumab (Phase II Trial Completion)atezolizumab

Therapy area: Oncology. Indication: Prostate Cancer

full page →atezolizumab →source: globaldata

Apr 30, 2026phase 2 completion104d agoHospital Of Dalian Medical University 1 — adebrelimab (Phase II Trial Completion)adebrelimab

Therapy area: Oncology. Indication: Adenocarcinoma Of The Gastroesophageal Junction, Gastric Cancer

full page →adebrelimab →source: globaldata

Apr 30, 2026phase 2 completion104d agoCancer Institute and Hospital Chinese Academy of Medical Sciences — capecitabine (Phase II Trial Completion)capecitabine

Therapy area: Oncology. Indication: Colorectal Cancer

full page →capecitabine →source: globaldata

Apr 30, 2026phase 2 completion104d agoNanfang Hospital of Southern Medical University — adebrelimab (Phase II Trial Completion)adebrelimab

Therapy area: Oncology. Indication: Small-Cell Lung Cancer

full page →adebrelimab →source: globaldata

← prev

page 5 of 5

Week of Apr 27, 2026